An evaluation of the FDA Responder Endpoint for IBS‐C clinical trials: analysis of data from linaclotide Phase 3 clinical trialsJ MacDougall, Anthony J Lembo, Valerie Williams et al.|Neurogastroenterology & Motility|2013Cited by 30
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS‐CMichael Camilleri, Jeffrey M. Johnston, Anthony Lembo et al.|United European Gastroenterology Journal|2014Cited by 17